Publication | Closed Access

Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

MedicinePharmacologySolid TumoursPharmacokinetic StudyPharmacotherapyTumor TargetingCancer TreatmentOncologyCancer Research